9,162 results match your criteria Respiratory medicine[Journal]


Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?

Lancet Respir Med 2019 Mar 12. Epub 2019 Mar 12.

Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30043-8DOI Listing

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

Lancet Respir Med 2019 Mar 12. Epub 2019 Mar 12.

David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA, USA.

Background: The anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line treatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer. We report updated 3-year safety and efficacy outcomes from the phase 1 study, KEYNOTE-001.

Methods: KEYNOTE-001 is a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in treatment naive or previously treated patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at baseline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30500-9DOI Listing

Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.

Lancet Respir Med 2019 Mar 12. Epub 2019 Mar 12.

University of Arizona College of Medicine, Department of Medicine, Tucson, AZ, USA.

Background: Small airways dysfunction (SAD) is well recognised in asthma, yet its role in the severity and control of asthma is unclear. This study aimed to assess which combination of biomarkers, physiological tests, and imaging markers best measure the presence and extent of SAD in patients with asthma.

Methods: In this baseline assessment of a multinational prospective cohort study (the Assessment of Small Airways Involvement in Asthma [ATLANTIS] study), we recruited participants with and without asthma (defined as Global Initiative for Asthma severity stages 1-5) from general practices, the databases of chest physicians, and advertisements at 29 centres across nine countries (Brazil, China, Germany, Italy, Spain, the Netherlands, the UK, the USA, and Canada). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30049-9DOI Listing

Listening in the quiet zone: will evaluation of small airways pay off?

Lancet Respir Med 2019 Mar 12. Epub 2019 Mar 12.

Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30051-7DOI Listing

The world is failing on silicosis.

Lancet Respir Med 2019 Mar 11. Epub 2019 Mar 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30078-5DOI Listing

Tobacco control in Jordan.

Authors:
Talha Khan Burki

Lancet Respir Med 2019 Mar 11. Epub 2019 Mar 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30077-3DOI Listing

The role of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Expert Rev Respir Med 2019 Mar 14. Epub 2019 Mar 14.

c Dpt of Medical Oncology , University Hospital of Larissa.

Introduction: Cancer immunotherapy represents a major therapeutic breakthrough. Immune checkpoint inhibitors alone or in the context of a combination are considered the new standard of care in advanced non-small cell lung cancer (NSCLC). Areas covered: This review explains the biologic rationale behind the implementation of immune checkpoint inhibitors for the therapy of advanced NSCLC. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17476348.2019.1
Publisher Site
http://dx.doi.org/10.1080/17476348.2019.1593828DOI Listing
March 2019
1 Read

New guidelines for home oxygen therapy in children.

Authors:
Susan Rahimi

Lancet Respir Med 2019 Mar 8. Epub 2019 Mar 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30076-1DOI Listing

Effects of health literacy and cognitive abilities on COPD self-management behaviors: A prospective cohort study.

Respir Med 2019 Feb 14. Epub 2019 Feb 14.

Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Introduction: Low rates of adherence to self-management behaviors are common among patients with COPD. Health literacy and cognitive abilities may influence engagement in self-management behaviors. We sought to assess the association between health literacy and cognitive abilities with self-management behaviors in patients with COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.02.006DOI Listing
February 2019
1 Read

Progress needed in bronchopulmonary dysplasia.

Authors:
Ammara Mushtaq

Lancet Respir Med 2019 Mar 1. Epub 2019 Mar 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30075-XDOI Listing

Blood monocyte profiles in COPD patients with PiMM and PiZZ α1-antitrypsin.

Respir Med 2019 Mar 6;148:60-62. Epub 2019 Feb 6.

Department of Respiratory Medicine, Hannover Medical School, Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), Member of German Centre for Lung Research (DZL), Hannover, Germany. Electronic address:

Human blood monocytes are divided into populations based on the differential expression of CD14 and CD16 receptors: CD14  CD16(classical), CD14  CD16  (intermediate), and CD14CD16 (non-classical). Given their functional differences and their role in pathogenesis of chronic obstructive pulmonary disease (COPD), monocyte profiling is of clinical interest. Here we investigated blood monocyte subsets in clinically stable COPD patients with alpha1-antitrypsin (AAT) deficiency (PiZZ, n = 7) and with normal AAT variant (PiMM, n = 7). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.02.001DOI Listing
March 2019
1 Read

Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis.

Respir Med 2019 Mar 24;148:6-12. Epub 2019 Jan 24.

Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA.

Background: Functional status, an important predictor of health outcomes in older patients, has not been studied in an IPF population. This study aimed to determine the prevalence of frailty and geriatric conditions in older patients with IPF.

Methods: IPF patients age ≥65 years were identified prospectively at the University of Michigan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.01.008DOI Listing

Correlation of spirometry and body plethysmography during exercise-induced bronchial obstruction.

Respir Med 2019 Mar 29;148:54-59. Epub 2019 Jan 29.

Department for Children and Adolescents, Allergy, Pulmonology, and Cystic Fibrosis, University Hospital Frankfurt, Goethe University, Germany. Electronic address:

Background: The exercise challenge is the gold standard for diagnosing exercise-induced bronchoconstriction (EIB). Airway obstructions appear up to 30 min after the challenge, with a maximum decrease in spirometry and a maximum increase in airway resistance. There is evidence that changes in body plethysmography parameters are more sensitive to the exercise challenge and precede those in spirometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.01.011DOI Listing
March 2019
1 Read

Mepolizumab improves small airway function in severe eosinophilic asthma.

Respir Med 2019 Mar 1;148:49-53. Epub 2019 Feb 1.

Department of Thoracic Medicine, Concord Hospital, Sydney, Australia; Faculty of Medicine and Health, Sydney University, Australia.

Background And Objective: Treatment with mepolizumab in severe eosinophilic asthma (SEA) significantly reduces exacerbations with modest improvements in symptom control and spirometry. The time course of any changes in small airway function is unknown.

Objective: To describe changes in ventilation inhomogeneity, a marker of small airway function, after commencing mepolizumab. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09546111193003
Publisher Site
http://dx.doi.org/10.1016/j.rmed.2019.01.016DOI Listing
March 2019
6 Reads

Monitoring peak expiratory flow could predict COPD exacerbations: A prospective observational study.

Respir Med 2019 Mar 24;148:43-48. Epub 2019 Jan 24.

Department of Respiratory Medicine, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, Zhejiang, China. Electronic address:

Background: Exacerbation of chronic obstructive pulmonary disease (ECOPD) is an important event during the course of the disease. It causes a more rapid decline in lung function, which is associated with hospitalization and the risk of death. Therefore, it is essential to discover approaches to early detection and prevention of ECOPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.01.010DOI Listing

Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.

Respir Med 2019 Mar 30;148:37-42. Epub 2019 Jan 30.

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address:

Background: Mycobacterium kansasii is a major pathogen associated with nontuberculous mycobacterial pulmonary disease. For treatment of M. kansasii pulmonary disease, daily therapy with isoniazid, rifampin, and ethambutol is traditionally recommended. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.01.012DOI Listing

18-year evolution of asthma and allergic diseases in French urban schoolchildren in relation to indoor air pollutant levels.

Respir Med 2019 Mar 24;148:31-36. Epub 2019 Jan 24.

Pulmonology Unit, La Timone Hospital, Marseille and Aix-Marseille University, France. Electronic address:

Background: An initial epidemiological study carried out 18 years ago in Marseilles indicated that the air quality in schools was poor and that there was an association between the level of fine particulates and the occurrence of asthma in children. The aim of the present study was to evaluate the change in the prevalence of childhood asthma and allergic diseases and their link with the levels of air pollutants and other factors of potential risk.

Methods: In 2016, using a questionnaire identical to the one used for the 1st survey in 1998-1999, we collected information regarding the symptoms, the diagnosis, and the potential confounding factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.01.007DOI Listing
March 2019
2 Reads

Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: A randomised controlled trial.

Respir Med 2019 Mar 28;148:24-30. Epub 2019 Jan 28.

Department of Cardiopulmonary Physiotherapy and Rehabilitation, Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Bezmialem Vakif University, Istanbul, 34060, Turkey. Electronic address:

Background: Previous research has found conflictive results regarding the benefits of inspiratory muscle training (IMT) for cystic fibrosis (CF) patients. Also, involvement of postural stability is a rising concern in chronic lung diseases but its role in CF patients is poorly understood. Our aim was to investigate the effects of IMT in CF patients as well as analysing the factors which may be related to postural stability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.01.013DOI Listing
March 2019
1 Read

Predictive and modifying factors of bone mineral density decline in patients with COPD.

Respir Med 2019 Mar 17;148:13-23. Epub 2019 Jan 17.

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Rationale: Various determinants of osteoporosis have been previously identified. However, only a few longitudinal studies have examined related factors. We aimed to investigate factors predicting and modifying rapid decline of bone mineral density in patients with chronic obstructive pulmonary disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.01.005DOI Listing
March 2019
1 Read

Vitamin D and disease severity in bronchiectasis.

Respir Med 2019 Mar 24;148:1-5. Epub 2019 Jan 24.

Respiratory Medicine, AOU "Policlinico - Vittorio Emanuele", University of Catania, Catania, Italy.

Background: Bronchiectasis is a complex respiratory disease characterised by permanent dilatation of bronchi. Vitamin D plays a role in infective disease by modulating the inflammation. Patients affected by bronchiectasis are frequently Vitamin D deficient and it correlates with lung function decline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.01.009DOI Listing
March 2019
1 Read

Correction to Lancet Respir Med 2018; 6: 747-58.

Authors:

Lancet Respir Med 2019 Feb 29;7(2):e9. Epub 2019 Jan 29.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30006-2DOI Listing
February 2019

Biologics for paediatric severe asthma: trick or TREAT?

Lancet Respir Med 2019 Feb 26. Epub 2019 Feb 26.

Department of Women's & Children's Health, University of Liverpool, Liverpool, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30045-1DOI Listing
February 2019
1 Read

Correction to Lancet Respir Med 2019; 7: 115-28.

Authors:

Lancet Respir Med 2019 Mar;7(3):e12

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30032-3DOI Listing

Our patients and our planet-holistic considerations for inhaler choice.

Lancet Respir Med 2019 Mar;7(3):e11

Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Sciences Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30035-9DOI Listing

Smoking prevalence and chronic diseases in China.

Lancet Respir Med 2019 Mar;7(3):e10

Shifa College of Medicine, Islamabad, Pakistan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30034-7DOI Listing

Asthma control: learning from Finland's success.

Authors:
Talha Khan Burki

Lancet Respir Med 2019 Mar;7(3):207-208

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30030-XDOI Listing

The way forward for tuberculosis vaccines.

Lancet Respir Med 2019 Mar;7(3):204-206

TB Modelling Group, TB Centre and Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30040-2DOI Listing

Screening for tuberculosis: time to move beyond symptoms.

Lancet Respir Med 2019 Mar;7(3):202-204

FIND, Campus Biotech, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30039-6DOI Listing

Spotting the old foe-revisiting the case definition for TB.

Lancet Respir Med 2019 Mar;7(3):199-201

Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30038-4DOI Listing

Isoniazid preventive therapy for children in sub-Saharan Africa.

Lancet Respir Med 2019 Mar;7(3):197-199

Division of Infection and Immunity, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals, London NW1 2PG, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30037-2DOI Listing

Towards optimal treatment for latent Mycobacterium tuberculosis infection.

Lancet Respir Med 2019 Mar;7(3):195-197

Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK; National Institute of Health Research Biomedical Research Centre, University College London Hospitals, London NW1 2PG, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30036-0DOI Listing

E-cigarette use and subsequent smoking in adolescents and young adults: a perspective.

Expert Rev Respir Med 2019 Mar 1:1-3. Epub 2019 Mar 1.

a Department of Health Sciences , University of York , Heslington , York , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2019.1589371DOI Listing

Advances in synthetic lung surfactant protein technology.

Expert Rev Respir Med 2019 Feb 28:1-3. Epub 2019 Feb 28.

a David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2019.1589372DOI Listing
February 2019
1 Read

Drowning is never dry.

Expert Rev Respir Med 2019 Feb 28:1-3. Epub 2019 Feb 28.

c Department of Pediatrics , University of Washington School of Medicine , Seattle , WA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2019.1589373DOI Listing
February 2019
1 Read

Emerging approaches in pediatric mechanical ventilation.

Expert Rev Respir Med 2019 Feb 26. Epub 2019 Feb 26.

b Division of Pediatric Critical Care Medicine, Department of Pediatrics , Duke Children's Hospital , Durham , NC , USA.

Introduction: The use of mechanical ventilation is an invaluable tool in caring for critically ill patients. Enhancing our capabilities in mechanical ventilation has been instrumental in the ability to support clinical conditions and diseases which were once associated with a high mortality. Areas covered: Within this manuscript, we will look to discuss emerging approaches to improving the care of pediatric patients who require mechanical ventilation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2019.1586536DOI Listing
February 2019

Impact of eHealth on medication adherence among patients with asthma: A systematic review and meta-analysis.

Respir Med 2019 Feb 15. Epub 2019 Feb 15.

Department of Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA. Electronic address:

Background: Asthma is an important public health issue in the United States. eHealth technology offers a potential solution to asthma treatment adherence, but the relative effect of various types of eHealth interventions has not been systematically studied.

Objectives: To systematically review the effectiveness of eHealth in improving adherence to inhaled corticosteroids (ICS) among patients with persistent asthma, as well as the satisfaction of patients undergoing eHealth interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.02.011DOI Listing
February 2019

Characteristics at the time of oxygen initiation associated with its adherence: Findings from the COPD Long-term Oxygen Treatment Trial.

Respir Med 2019 Feb 13. Epub 2019 Feb 13.

University of Colorado School of Medicine, Aurora, CO, USA.

Rationale: Characteristics associated with adherence to long-term oxygen therapy (LTOT) in COPD remain unclear.

Objectives: To identify patient characteristics at the time of oxygen initiation associated with its adherence.

Methods: We conducted a secondary analysis of data from 359 COPD participants assigned to oxygen in the Long-term Oxygen Treatment Trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.02.004DOI Listing
February 2019
1 Read

Effect of a mHealth intervention on adherence in adolescents with asthma: A randomized controlled trial.

Respir Med 2019 Feb 16. Epub 2019 Feb 16.

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, the Netherlands. Electronic address:

Background: Adherence rates among asthma patients are generally low and decrease during adolescence, resulting in poorly controlled asthma. The aim of our study was to evaluate the effectiveness of the ADolescent Adherence Patient Tool (ADAPT), an interactive mobile health (mHealth) intervention, in supporting self-management and improving inhaled corticosteroid adherence in adolescents with asthma.

Methods: We conducted a cluster randomized controlled trial in 66 Dutch community pharmacies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.02.009DOI Listing
February 2019

Diagnosing and managing bronchiolitis obliterans in children.

Expert Rev Respir Med 2019 Feb 23:1-8. Epub 2019 Feb 23.

a Respiratory Unit , Great Ormond Street Hospital for Children NHS Foundation Trust , London , UK.

Introduction: Bronchiolitis obliterans (BO) is a chronic and irreversible obstructive lung disease leading to the obstruction and/or obliteration of the small airways. Three main BO entities are distinguished: post-infectious BO (PIBO); BO post lung transplantation; and BO after bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT). All three entities are separate, however, there are similarities in histopathological characteristics and possibly in aspects of the development pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2019.1586537DOI Listing
February 2019
1 Read

Molecular biomarkers for the evaluation of lung nodules.

Authors:
Peter J Mazzone

Lancet Respir Med 2019 Feb 15. Epub 2019 Feb 15.

Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30528-9DOI Listing
February 2019

Sarcoidosis: No longer a benign disease?

Authors:
Alicia K Gerke

Respir Med 2019 Feb 6. Epub 2019 Feb 6.

University of Iowa, Pulmonary and Critical Care Medicine, 200 Hawkins Dr. C33-GH, Iowa City, IA, 52242, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.02.002DOI Listing
February 2019
1 Read

Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial.

Lancet Respir Med 2019 Feb 13. Epub 2019 Feb 13.

Departments of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Thoracic Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address:

Background: In patients with non-expandable lung, removal of pleural fluid can result in excessively negative pleural pressure, which is associated with chest discomfort, pneumothorax, and re-expansion pulmonary oedema. Pleural manometry is widely used to safeguard against pressure-related complications during thoracentesis despite little evidence to support the approach. We investigated whether monitoring of pleural pressure with manometry during thoracentesis could protect against complications compared with assessment of symptoms alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30421-1DOI Listing
February 2019
1 Read

Pleural manometry and thoracentesis-is the issue resolved?

Lancet Respir Med 2019 Feb 13. Epub 2019 Feb 13.

Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097 Warsaw, Poland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22132600193003
Publisher Site
http://dx.doi.org/10.1016/S2213-2600(19)30033-5DOI Listing
February 2019
4 Reads

Urgent action on antimicrobial resistance.

Authors:
Susan Rahimi

Lancet Respir Med 2019 Mar 12;7(3):208-209. Epub 2019 Feb 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30031-1DOI Listing

Lung function trajectories in health and disease.

Lancet Respir Med 2019 Feb 11. Epub 2019 Feb 11.

August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona, Spain; Centro de Investigación Biomédica en Red, Enfermedades Respiratorias, Instituto de Salud Carlos III (CIBER), Madrid, Spain.

The normal lung function trajectory from birth to death has three phases: a growth phase (from birth to early adulthood), a plateau phase (that lasts for a few years), and a decline phase resulting from physiological lung ageing. Numerous genetic and environmental factors can alter one or more of these phases. Evidence shows that several lung function trajectories exist throughout the life course and, importantly, that some of them are associated with substantial implications for health and disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30529-0DOI Listing
February 2019

Emphysema: looking beyond alpha-1 antitrypsin deficiency.

Expert Rev Respir Med 2019 Feb 14:1-17. Epub 2019 Feb 14.

b Department of Respiratory Medicine , Maastricht University Medical Center , Maastricht , The Netherlands.

Introduction: Distinct pathologies can cause chronic obstructive pulmonary disease (COPD). Emphysema is a COPD-phenotype characterized by destruction of lung parenchyma. Alpha-1 antitrypsin deficiency (AATD) is a genetic cause of emphysema, whereas smoking is the most important risk factor of non-AATD emphysema. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2019.1580575DOI Listing
February 2019
4 Reads

Lung volume reduction for severe emphysema: good things come in small packages.

Authors:
Surya P Bhatt

Lancet Respir Med 2019 Feb 7. Epub 2019 Feb 7.

Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA; UAB Lung Imaging Core and UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30494-6DOI Listing
February 2019
1 Read

Burnout in women intensivists: a hidden epidemic?

Lancet Respir Med 2019 Feb 7. Epub 2019 Feb 7.

Division of Critical Care Medicine and Center for Health Evaluation and Outcome Sciences, St. Paul's Hospital and University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30029-3DOI Listing
February 2019
1 Read

Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis.

Lancet Respir Med 2019 Feb 7. Epub 2019 Feb 7.

Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital, London, UK; National Heart & Lung Institute, Imperial College, London, UK; Chelsea and Westminster Hospital NHS Foundation Trust, London, UK. Electronic address:

Background: Severe emphysema is a debilitating condition with few treatment options. Lung volume reduction procedures in the treatment of severe emphysema have shown excellent results in selected patients but their exact role remains unclear with studies reporting a wide variation in outcomes. We therefore aimed to evaluate the effects of volume reduction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30431-4DOI Listing
February 2019
2 Reads